Side effects from acute myeloid leukemia treatment: results from a national survey

Norah L. Crossnohere, Daniel R. Richardson, Crystal Reinhart, Bernadette O’Donoghue, Susan M. Love, B. Douglas Smith, John F.P. Bridges

Research output: Contribution to journalArticle

Abstract

Objective: Acute myeloid leukemia (AML) is experiencing a therapeutic renaissance due to the heightened biomedical understanding of AML and patient-focused drug development (PFDD). Many AML patients now live long-term with the side effects of treatment. This study documents the prevalence and severity of AML treatment-related side effects. Methods: A national cross-sectional survey designed with the Leukemia & Lymphoma Society assessed patients’ experiences with short-term (nausea/vomiting, diarrhea, hair loss, mouth sores, infection, rash) and long-term (organ dysfunction, chemobrain, fatigue, neuropathy) treatment side effects. Patient and caregiver participants rated side effect severity (none–severe). Results: Survey participants (n = 1182) were mostly female (65%), AML patients (76%), and had undergone chemotherapy (94%). Eighty-seven per cent of participants reported severe short-term effects, and 33% reported severe long-term effects of treatment. Only 11% of respondents did not have any severe effects. Hair loss and fatigue were the most common severe short- and long-term side effects (78%, 33%). There was a moderate correlation between having short- and long-term adverse effects (r = 0.41, p < 0.001). Caregivers were more likely than patients to report severe organ dysfunction, fatigue, and neuropathy (p-values < 0.05). Conclusions: Survivors experience a high burden of side effects from AML treatments highlighting the need for the development of less toxic therapies. Differences in patients’ and caregivers’ experiences illustrate the importance of sampling from diverse sources to understand the full burden of AML treatment, and the need for less toxic drugs. This study informs patients, patient-advocacy groups, clinicians, and regulators about AML treatment burdens and provides the community with information to inform PFDD.

Original languageEnglish (US)
Pages (from-to)1965-1970
Number of pages6
JournalCurrent Medical Research and Opinion
Volume35
Issue number11
DOIs
StatePublished - Nov 2 2019

Fingerprint

Acute Myeloid Leukemia
Caregivers
Fatigue
Therapeutics
Poisons
Alopecia
Cross-Sectional Studies
Pharmaceutical Preparations
Patient Advocacy
Surveys and Questionnaires
Exanthema
Nausea
Vomiting
Survivors
Mouth
Diarrhea
Lymphoma
Leukemia
Drug Therapy
Infection

Keywords

  • Adverse effects
  • Long-term adverse effects
  • Patient-focused drug development
  • Quality-of-life: Treatment outcome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Crossnohere, N. L., Richardson, D. R., Reinhart, C., O’Donoghue, B., Love, S. M., Smith, B. D., & Bridges, J. F. P. (2019). Side effects from acute myeloid leukemia treatment: results from a national survey. Current Medical Research and Opinion, 35(11), 1965-1970. https://doi.org/10.1080/03007995.2019.1631149

Side effects from acute myeloid leukemia treatment : results from a national survey. / Crossnohere, Norah L.; Richardson, Daniel R.; Reinhart, Crystal; O’Donoghue, Bernadette; Love, Susan M.; Smith, B. Douglas; Bridges, John F.P.

In: Current Medical Research and Opinion, Vol. 35, No. 11, 02.11.2019, p. 1965-1970.

Research output: Contribution to journalArticle

Crossnohere, NL, Richardson, DR, Reinhart, C, O’Donoghue, B, Love, SM, Smith, BD & Bridges, JFP 2019, 'Side effects from acute myeloid leukemia treatment: results from a national survey', Current Medical Research and Opinion, vol. 35, no. 11, pp. 1965-1970. https://doi.org/10.1080/03007995.2019.1631149
Crossnohere, Norah L. ; Richardson, Daniel R. ; Reinhart, Crystal ; O’Donoghue, Bernadette ; Love, Susan M. ; Smith, B. Douglas ; Bridges, John F.P. / Side effects from acute myeloid leukemia treatment : results from a national survey. In: Current Medical Research and Opinion. 2019 ; Vol. 35, No. 11. pp. 1965-1970.
@article{213d2cb193fd4ba2b0aa39198a0e4b63,
title = "Side effects from acute myeloid leukemia treatment: results from a national survey",
abstract = "Objective: Acute myeloid leukemia (AML) is experiencing a therapeutic renaissance due to the heightened biomedical understanding of AML and patient-focused drug development (PFDD). Many AML patients now live long-term with the side effects of treatment. This study documents the prevalence and severity of AML treatment-related side effects. Methods: A national cross-sectional survey designed with the Leukemia & Lymphoma Society assessed patients’ experiences with short-term (nausea/vomiting, diarrhea, hair loss, mouth sores, infection, rash) and long-term (organ dysfunction, chemobrain, fatigue, neuropathy) treatment side effects. Patient and caregiver participants rated side effect severity (none–severe). Results: Survey participants (n = 1182) were mostly female (65{\%}), AML patients (76{\%}), and had undergone chemotherapy (94{\%}). Eighty-seven per cent of participants reported severe short-term effects, and 33{\%} reported severe long-term effects of treatment. Only 11{\%} of respondents did not have any severe effects. Hair loss and fatigue were the most common severe short- and long-term side effects (78{\%}, 33{\%}). There was a moderate correlation between having short- and long-term adverse effects (r = 0.41, p < 0.001). Caregivers were more likely than patients to report severe organ dysfunction, fatigue, and neuropathy (p-values < 0.05). Conclusions: Survivors experience a high burden of side effects from AML treatments highlighting the need for the development of less toxic therapies. Differences in patients’ and caregivers’ experiences illustrate the importance of sampling from diverse sources to understand the full burden of AML treatment, and the need for less toxic drugs. This study informs patients, patient-advocacy groups, clinicians, and regulators about AML treatment burdens and provides the community with information to inform PFDD.",
keywords = "Adverse effects, Long-term adverse effects, Patient-focused drug development, Quality-of-life: Treatment outcome",
author = "Crossnohere, {Norah L.} and Richardson, {Daniel R.} and Crystal Reinhart and Bernadette O’Donoghue and Love, {Susan M.} and Smith, {B. Douglas} and Bridges, {John F.P.}",
year = "2019",
month = "11",
day = "2",
doi = "10.1080/03007995.2019.1631149",
language = "English (US)",
volume = "35",
pages = "1965--1970",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Side effects from acute myeloid leukemia treatment

T2 - results from a national survey

AU - Crossnohere, Norah L.

AU - Richardson, Daniel R.

AU - Reinhart, Crystal

AU - O’Donoghue, Bernadette

AU - Love, Susan M.

AU - Smith, B. Douglas

AU - Bridges, John F.P.

PY - 2019/11/2

Y1 - 2019/11/2

N2 - Objective: Acute myeloid leukemia (AML) is experiencing a therapeutic renaissance due to the heightened biomedical understanding of AML and patient-focused drug development (PFDD). Many AML patients now live long-term with the side effects of treatment. This study documents the prevalence and severity of AML treatment-related side effects. Methods: A national cross-sectional survey designed with the Leukemia & Lymphoma Society assessed patients’ experiences with short-term (nausea/vomiting, diarrhea, hair loss, mouth sores, infection, rash) and long-term (organ dysfunction, chemobrain, fatigue, neuropathy) treatment side effects. Patient and caregiver participants rated side effect severity (none–severe). Results: Survey participants (n = 1182) were mostly female (65%), AML patients (76%), and had undergone chemotherapy (94%). Eighty-seven per cent of participants reported severe short-term effects, and 33% reported severe long-term effects of treatment. Only 11% of respondents did not have any severe effects. Hair loss and fatigue were the most common severe short- and long-term side effects (78%, 33%). There was a moderate correlation between having short- and long-term adverse effects (r = 0.41, p < 0.001). Caregivers were more likely than patients to report severe organ dysfunction, fatigue, and neuropathy (p-values < 0.05). Conclusions: Survivors experience a high burden of side effects from AML treatments highlighting the need for the development of less toxic therapies. Differences in patients’ and caregivers’ experiences illustrate the importance of sampling from diverse sources to understand the full burden of AML treatment, and the need for less toxic drugs. This study informs patients, patient-advocacy groups, clinicians, and regulators about AML treatment burdens and provides the community with information to inform PFDD.

AB - Objective: Acute myeloid leukemia (AML) is experiencing a therapeutic renaissance due to the heightened biomedical understanding of AML and patient-focused drug development (PFDD). Many AML patients now live long-term with the side effects of treatment. This study documents the prevalence and severity of AML treatment-related side effects. Methods: A national cross-sectional survey designed with the Leukemia & Lymphoma Society assessed patients’ experiences with short-term (nausea/vomiting, diarrhea, hair loss, mouth sores, infection, rash) and long-term (organ dysfunction, chemobrain, fatigue, neuropathy) treatment side effects. Patient and caregiver participants rated side effect severity (none–severe). Results: Survey participants (n = 1182) were mostly female (65%), AML patients (76%), and had undergone chemotherapy (94%). Eighty-seven per cent of participants reported severe short-term effects, and 33% reported severe long-term effects of treatment. Only 11% of respondents did not have any severe effects. Hair loss and fatigue were the most common severe short- and long-term side effects (78%, 33%). There was a moderate correlation between having short- and long-term adverse effects (r = 0.41, p < 0.001). Caregivers were more likely than patients to report severe organ dysfunction, fatigue, and neuropathy (p-values < 0.05). Conclusions: Survivors experience a high burden of side effects from AML treatments highlighting the need for the development of less toxic therapies. Differences in patients’ and caregivers’ experiences illustrate the importance of sampling from diverse sources to understand the full burden of AML treatment, and the need for less toxic drugs. This study informs patients, patient-advocacy groups, clinicians, and regulators about AML treatment burdens and provides the community with information to inform PFDD.

KW - Adverse effects

KW - Long-term adverse effects

KW - Patient-focused drug development

KW - Quality-of-life: Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=85073584202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073584202&partnerID=8YFLogxK

U2 - 10.1080/03007995.2019.1631149

DO - 10.1080/03007995.2019.1631149

M3 - Article

C2 - 31188058

AN - SCOPUS:85073584202

VL - 35

SP - 1965

EP - 1970

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 11

ER -